Clinical Trials Arena August 28, 2024
Given its high prevalence and overlap with other metabolic conditions, there is a critical need to find effective solutions to address the significant economic and health burdens MASH imposes on society.
The emergence of incretin-modulating therapies has transformed the way healthcare providers are tackling the obesity pandemic. With groundbreaking drugs such as Wegovy (semaglutide) and Zepbound (tirzepatide) now revolutionising chronic weight management, emerging evidence is shedding light on their broader impact—not just on weight, but on vital organs like the heart, kidneys, and liver. These advancements are opening new doors in the fight against comorbidities, offering hope for a more holistic treatment approach in patients suffering from metabolic dysfunction-associated steatohepatitis (MASH). Given its high prevalence and overlap with other metabolic...
Today's Sponsors
Today's Sponsor